Why Verona Pharma plc (VRNA) Took Off on Tuesday

We have recently released an article entitled Why These 10 Shares Gained Ground Today In this piece, we will examine how Verona Pharma plc (NASDAQ:VRNA) measures up against other stocks that saw significant gains on Tuesday.

The stock market closed out Tuesday’s trading session on an upbeat note as all key indexes ended up in positive territory, driven by a wave of incoming corporate earnings reports.

The Dow Jones increased by 0.75 percent, the S&P 500 climbed by 0.58 percent, and the Nasdaq gained 0.55 percent.

Ten firms echoed the overall market positivity, spearheading advances primarily fueled by robust financial outcomes.

For compiling this list, we took into account solely those stocks which have a market capitalization of at least $2 billion and exhibit a daily trading volume of $5 million or more.

An individual at a healthcare facility is inhaling medicine through a nebulizer to address a lung condition.

Verona Pharma plc (NASDAQ:VRNA)

On Tuesday, Verona Pharma plc (NASDAQ:VRNA) continued its upward trend for the eighth consecutive day, surging by 6.37% to close at $73.21 per share following strong financial results in the initial quarter of the year.

Verona Pharma plc (NASDAQ:VRNA), in its earnings statement, reported reducing its net loss by 36.8 percent to $16.3 million from $25.79 million during the corresponding timeframe of the previous year.

The net revenue amounted to $76.3 million, largely due to $71.3 million in net sales generated by Ohtuvayre, which is the company’s maintenance therapy for COPD.

This past February, Verona Pharma plc (NASDAQ:VRNA), working with their partner Nuance Pharma, received approval from the Macau government to market Ohtuvayre within the special administrative region.

In response to their impressive performance, VRNA President and CEO David Zaccardelli commented, "We are exceptionally delighted to announce that for the very first time, Verona has achieved a quarter where its revenues surpassed operational expenditures, not including non-recurring costs. This indicates that we have a solid fiscal standing which will enable us to keep promoting Ohtuvayre, progress our clinical development initiatives, and execute our worldwide plan."

Overall VRNA ranks 6th On our list of stocks that surged on Tuesday, although we recognize the potential of VRNA as an investment, we firmly believe that AI stocks offer better prospects for generating higher returns over a shorter period. One particular AI stock has seen gains since the start of 2025, even though many well-known AI stocks have dropped by approximately 25% during the same timeframe. Should you be seeking an AI stock with stronger growth potential compared to VRNA yet trading below five times its earnings, consider reviewing our detailed analysis on this subject. cheapest AI stock .

READ NEXT: 20 Top AI Stocks You Should Consider Purchasing Today and 30 Top Stocks to Purchase Currently as Recommended by Billionaires .

Disclosure: There are no conflicts of interest. This article was initially published here. Insider Monkey .

Share :